# HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)

> **NCT03685708** · PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 78 (actual)

## Conditions studied

- Hepatitis
- Safety and Tolerability

## Interventions

- **BIOLOGICAL:** HEPLISAV-B

## Key facts

- **NCT ID:** NCT03685708
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-07
- **Primary completion:** 2020-12-16
- **Final completion:** 2020-12-16
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03685708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03685708, "HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03685708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*